Medicinal fungi: a source of antiparasitic secondary metabolites

Lenzi, Juliana; Costa, Tania Maria; Alberton, Michele Debiasi; Greinert-Goulart, Juliane Araújo; Tavares, Lorena Benathar Ballod

doi:10.1007/s00253-018-9048-8

Cited by 29 publications

(21 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2020 microrganismos, os quais são considerados verdadeiras biofábricas (SOUZA et al, 2016, MATOS LINS et al, 2018. Os fungos basidiomicetos mostram ampla capacidade de desenvolvimento em substratos sólidos (ZENNI; HELM; TAVARES, 2018) e líquidos (LENZI et al, 2018), podendo gerar produtos de interesse à indústria de alimentos, fármacos e cosméticos (BENTO;CASARIL, 2012). Fungos do gênero Ganoderma, tais como G. lucidum, G. applanatum, G. tsugae, G. lingzhi, G. et al 2017).…”

Section: Introductionunclassified

INFLUÊNCIA DO RESÍDUO DE PRODUÇÃO DE CERVEJA NO CRESCIMENTO DE FUNGOS Ganoderma E NA OBTENÇÃO DE β-GLUCANAS

Schipmann

Timm

Costa³

et al. 2021

R. Est. ambient.

Self Cite

View full text Add to dashboard Cite

A utilização de efluentes do setor cervejeiro como substrato em cultivos fúngicos torna-se uma alternativa sustentável de reaproveitamento de resíduos. Este trabalho avaliou a velocidade de crescimento micelial radial (Vm) e a produção de β-glucanas pelos fungos Ganoderma lipsiense e Ganoderma applanatum cultivados em placas de Petri contendo resíduo da centrifugação da cerveja Pilsen (RCP), previamente caracterizado quimicamente, nas concentrações bruta (T1), diluído 50% (T2) e 75% (T3), com medições radiais diárias durante 13 dias. Ao término deste período, os micélios foram removidos realizando-se posterior secagem (55°C) para quantificação de β-glucanas. A caracterização química do resíduo indicou a presença de fósforo (81,20 mg L-1), nitrogênio amoniacal (9,18 mg L-1), além de DBO (17.750,00 mg O2 L-1) e DQO (32.050,00 mg O2 L-1). Todas as concentrações de resíduo proporcionaram crescimento micelial e produção de β-glucanas. Em T1, foram obtidos maiores Vm (4,48 e 3,90 mm dia-1) para G. applanatum e G. lipsiense. Em relação as β-glucanas, G. lipsiense apresentou maiores teores (32 %) no T2 e 30,28% no T1, enquanto G. applanatum produziu teores abaixo de 20%. Os resultados mostram a influência da concentração do meio de cultivo e da espécie fúngica na produção de biocompostos e sugerem que o RCP estudado pode ser reaproveitado, sendo empregado como substrato para produção de compostos de interesse farmacêutico, tais como β-glucanas.

show abstract

Section: Introductionunclassified

INFLUÊNCIA DO RESÍDUO DE PRODUÇÃO DE CERVEJA NO CRESCIMENTO DE FUNGOS Ganoderma E NA OBTENÇÃO DE β-GLUCANAS

Schipmann

Timm

Costa³

et al. 2021

R. Est. ambient.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Microbial metabolites are essential resources for drug discovery (Lenzi et al, 2018). Compared with other natural product resources, fungi have the following advantages.…”

Section: Introductionmentioning

confidence: 99%

A diverse global fungal library for drug discovery

Niu

Annamalai

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Background Secondary fungal metabolites are important sources for new drugs against infectious diseases and cancers. Methods To obtain a library with enough diversity, we collected about 2,395 soil samples and 2,324 plant samples from 36 regions in Africa, Asia, and North America. The collection areas covered various climate zones in the world. We examined the usability of the global fungal extract library (GFEL) against parasitic malaria transmission, Gram-positive and negative bacterial pathogens, and leukemia cells. Results Nearly ten thousand fungal strains were isolated. Sequences of nuclear ribosomal internal transcribed spacer (ITS) from 40 randomly selected strains showed that over 80% were unique. Screening GFEL, we found that the fungal extract from Penicillium thomii was able to block Plasmodium falciparum transmission to Anopheles gambiae, and the fungal extract from Tolypocladium album was able to kill myelogenous leukemia cell line K562. We also identified a set of candidate fungal extracts against bacterial pathogens.

show abstract

“…Indeed, more than half of anti-tumor drugs or leads in current clinical trials are from natural products (Wolfender and Queiroz 2012). Microbial metabolites are essential resources for drug discovery (Lenzi, Costa et al 2018). Compared with other natural product resources, fungi have the following advantages.…”

Section: Introductionmentioning

confidence: 99%

Peer Review #2 of "A diverse global fungal library for drug discovery (v0.1)"

2020

View full text Add to dashboard Cite

Background. Secondary fungal metabolites are important sources for new drugs against infectious diseases and cancers. Methods. To obtain a library with enough diversity, we collected about 2395 soil samples and 2324 plant samples from 36 regions in Africa, Asia, and North America. The collection areas covered various climate zones in the world. We examined the usability of the global fungal extract library (GFEL) against parasitic malaria transmission, Gram-positive and negative bacterial pathogens, and leukemia cells. Results. Nearly ten thousand fungal strains were isolated. Sequences of nuclear ribosomal internal transcribed spacer (ITS) from 40 randomly selected strains showed that over 80% were unique. Screening GFEL, we found that the fungal extract from Penicillium thomii was able to block P. falciparum transmission to Anopheles gambiae, and the fungal extract from Tolypocladium album was able to kill myelogenous leukemia cell line K562. We also identified a set of candidate fungal extracts against bacterial pathogens.

show abstract

Medicinal fungi: a source of antiparasitic secondary metabolites

Cited by 29 publications

References 104 publications

INFLUÊNCIA DO RESÍDUO DE PRODUÇÃO DE CERVEJA NO CRESCIMENTO DE FUNGOS Ganoderma E NA OBTENÇÃO DE β-GLUCANAS

INFLUÊNCIA DO RESÍDUO DE PRODUÇÃO DE CERVEJA NO CRESCIMENTO DE FUNGOS Ganoderma E NA OBTENÇÃO DE β-GLUCANAS

A diverse global fungal library for drug discovery

Peer Review #2 of "A diverse global fungal library for drug discovery (v0.1)"

Contact Info

Product

Resources

About